With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck ...

Under the terms of the deal, MSD (known as Merck & Co in the US and Canada) is paying $30 million upfront for Modifi with up ...

Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, has been ...

After the disastrous performance of 2022, the market has recovered better than expected and is on a growth trajectory.

The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.

All adults aged 50 and older should receive a vaccine against bacteria that can cause pneumonia and meningitis, federal ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...

The CDC advisory panel noted that pneumococcal illness tends to appear earlier in Black Americans -- between 55 and 59 years ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck ( MRK -0 ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...